Brawn Biotech Freezes Trading April 1 for FY26 Results

HEALTHCAREBIOTECH
Whalesbook Corporate News Logo
AuthorIshaan Verma|Published at:
Brawn Biotech Freezes Trading April 1 for FY26 Results
Overview

Brawn Biotech Ltd. is closing its trading window for key employees and their families starting April 1, 2026. This standard practice, required by SEBI rules, prevents insider trading until 48 hours after the company releases its audited financial results for the fiscal year ending March 31, 2026.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • ✓Quarterly Results
  • ✓Concall Announcements
  • ✓New Orders & Big Deals
  • ✓Capex Announcements
  • ✓Bulk Deals
  • ✦And much more
Add StocksGet it on Google PlayDownload on the App Store

Brawn Biotech Closes Trading Window for FY26 Results

Brawn Biotech Ltd. announced today that it will close its trading window for designated persons and their immediate relatives. The window will be effective from April 1, 2026, and is a standard regulatory measure aimed at preventing potential insider trading before the company discloses its audited financial results for the fiscal year ending March 31, 2026.

The trading window is set to reopen 48 hours after the official declaration of these full-year results. This measure is in line with SEBI (Prohibition of Insider Trading) Regulations, 2015, designed to uphold market integrity and prevent any unfair advantage derived from non-public financial data.

This is a routine procedure for the company, which previously implemented a similar closure on October 1, 2024, ahead of its Q2 FY25 financial results. Companies in the sector, including Vivanza Biosciences Ltd., Kobo Biotech Ltd., and Dr. Lal PathLabs Ltd., also follow similar SEBI trading window compliance frameworks.

For the fiscal year ending March 31, 2025, Brawn Biotech reported revenue of ₹13.6 Crore. In the third quarter of fiscal year 2026 (ended December 31, 2025), revenue from operations stood at ₹5.10 Lakhs, with a net loss of ₹0.78 Lakhs.

While this is a common compliance step, strict adherence to SEBI's insider trading norms is crucial. Any deviation can lead to investigations and penalties. The company has been subject to SEBI disclosures regarding insider trading in the past, including a notable acquisition by Brij Raj Gupta in February 2016.

Investors will be monitoring for the announcement of the Board meeting date to approve the audited FY26 financial results. Key events to watch include the subsequent release of these audited results and the official reopening of the trading window.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Add Stocks
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.